ライフサイエンスコーパス: African American

1 dividuals (mean age 56 +/- 8.3, 68% men, 54% African American).

2 ge of 78 years, 54% were women, and 11% were African American.

3 ESRD patients were younger, male, and African American.

4 2) years, and 40% were Hispanic and 25% were African American.

5 60% were male, 40% Caucasian, and 30% Black/African American.

6 was 15 years, and 46.8% of the patients were African American.

7 423 participants, 1806 were men and 617 were African American.

8 rquartile range [IQR], 54, 66), and 23% were African American.

9 isproportionate burden of type 2 diabetes in African Americans.

10 showed stronger correlations with SIClamp in African Americans.

11 IC patients and 81% of the IBD patients were African Americans.

12 hitecture underlying expression variation in African Americans.

13 including 3754 continental Africans and 1867 African Americans.

14 ta-Catenin expression and colonic lesions in African Americans.

15 lower SIClamp in Caucasian Americans but not African Americans.

16 nges found in the skin of obese subjects and African Americans.

17 in continental Africans, with replication in African Americans.

18 the high frequency of nondiabetic CKD among African Americans.

19 ominant cause of C8alpha-gamma deficiency in African Americans.

20 f cancer has not been thoroughly examined in African Americans.

21 variant signals from stratified analysis of African Americans.

22 ma deficiency was examined in four unrelated African Americans.

23 parities in the outcome of the disease among African Americans.

24 tly correlated across European-Americans and African-Americans.

25 40% in Asians, ~16% in Europeans, and ~3% in African-Americans.

26 rate of MS in European-Americans compared to African-Americans.

27 ted with the genetic predisposition to CD in African-Americans.

28 ios for success were significantly lower for African-American (0.67; 95% confidence interval [CI] = 0

29 ed a case: control RNA sequencing study of 7 African American, 12 Middle Eastern subjects, and 7 cont

30 f European (1806 cases and 10,397 controls), African American (133 cases and 1,314 controls), and His

31 .5] years; 12 (50%] women; 14 [58%] black or African American; 14 [58%]), 23 (96%) completed the tria

32 5 years); 31% were female, 43% were black or African American, 15% were Asian, 56% had a body mass in

33 Among 1556 participants, 41% were white, 25% African American, 21% Hispanic, and 14% Chinese; 51% wer

34 Large pluralities of African American (25%, n = 27,242) and Hispanic individu

35 European American [23% current smokers], 101 African American [26% current smokers]) were analyzed.

36 Racial/ethnic characteristics (48% African American, 31% Hispanic/Latino, 14% white) and HI

37 lizer vs super-utilizer: 47.9% vs 54.2%) and African American (4.0% vs 7.2%), whereas 58.8% (n = 208,

38 2] years; 24 women [50%]; 23 white [48%], 23 African American [48%], 1 Asian [2%], and 1 of unknown r

39 .56% in Ashkenazi Jewish to 3.26% in African/African Americans (5.8-fold difference).

40 age was 44 years, 32% were female, 93% were African-American, 59% had recently injected drugs, and 2

41 an age 76 years; mean EF 28%; 41% women; 13% African American; 65% on beta-blockers) was assembled.

42 and four ancestries (6,158 Europeans, 3,123 African-Americans, 650 Hispanics, and 407 East Asians),

43 ents with HFpEF were more often women (59%), African American (68%), obese (median body mass index 41

44 predominantly HIV seropositive (68%), Black/African-American (68%) or Hispanic (16%), and low income

45 ears' follow-up was 11.3% in whites, 6.6% in African Americans, 7.8% in Hispanics, and 9.9% in Chines

46 ontinental Africans (P=5.0x10(-111)) and for African Americans (9.5x10(-38)), respectively explaining

47 In African Americans, a 5' untranslated region insertion (r

48 antibody subsets in a large, newly recruited African American (AA) cohort and among European American

49 less effective in improving knowledge among African American (AA) kidney transplant candidates compa

50 l disparity in prostate cancer (PCa) is that African American (AA) patients have a higher mortality r

51 e-scale in-depth eQTL mapping study on 1,032 African Americans (AA) and 801 European Americans (EA) i

52 The ADHD cases included 116 African Americans (AA) and 89 of European Ancestry (EA)

53 nalysis of BP response post CTD treatment in African Americans (AA) and European Americans (EA) from

54 African Americans (AA) are at high risk for Colorectal C

55 African Americans (AA) have lower rates of kidney transp

56 phenotypes (24-h, daytime, nighttime) among African Americans (AA).

57 interpersonal problems] were examined among African-American (AA) and White urban adults participati

58 associated with DR is two-fold higher in the African-American (AA) compared to non-Hispanic white.

59 cans for the DSM-IV diagnosis of OD in 8,387 African-American (AA) or European-American subjects (43.

60 omen (1,796 European-American (EA) and 1,349 African-American (AA)) enrolled in the Women's Health In

61 in 1295 sub-Saharan Africans (SSAs) with 559 African-Americans (AAms) and 2464 European-Americans (EA

62 African Americans (AAs) and Hispanic/Latinos (HLs) have

63 may exacerbate underlying disparities among African Americans (AAs) at increased risk.

64 ic on clinical presentations and outcomes in African Americans (AAs) compared to white patients.

65 ipt profile data measured in a cohort of 230 African Americans (AAs) from the African American Geneti

66 edicine whole genome sequencing data in 2249 African Americans (AAs) from the Jackson Heart Study, we

67 African Americans (AAs) suffer a disproportionate burden

68 ive laboratory test result for SARS-CoV-2 in African Americans after adjusting for age, sex, race, sm

69 dren treated with ICS (Hispanics/Latinos and African Americans), analysing 8.7 million genetic varian

70 ations with height in European Americans and African Americans ancestries.

71 nce for individuals of European-American and African-American ancestries.

72 India, Iran, Japan and Korea and samples of African American ancestry for all classical HLA class I

73 omen without diabetes mellitus, 73 black (58 African American and 15 African immigrant) and 49 white;

74 s, 31% were female (natal sex), 43% black or African American and 15% Asian, the median body mass ind

75 The mean age was 64.8 (SD = 7.5); 51% were African American and 64% were males.

76 African American and European American individuals have

77 10(-6) for admixture mapping studies in the African American and Hispanic/Latina cohorts, respective

78 Although the largest GWASs in African American and Latino/Hispanic populations were re

79 ip between aspects of COVID-19 messaging and African American and Latinx participants' knowledge and

80 Health Administration Health Care System of African American and non-Hispanic White men diagnosed wi

81 nd "Hispanic" members, and less progress for African American and other ethnic populations.

82 effects on pain report largely similarly in African American and other groups.

83 In African American and South Asian populations, cultural b

84 ary population-based studies of non-Hispanic African American and white adults aged 40-75 years with

85 ntified 671 somatic mutations in tumors from African Americans and 762 somatic mutations in tumors in

86 e and AD-associated IL-9 differences between African Americans and Caucasians point to distinct molec

87 the DNA repairome in prostate cancer between African Americans and Caucasians.

88 tumors and matched normal tissue samples in African Americans and Caucasians.

89 The intervention was equally effective in African Americans and Caucasians.

90 omprehensively phenotyped immune profiles of African Americans and European Americans who are ANA-neg

91 African Americans and Latinos are overrepresented among

92 on symptoms and seek testing, compared with African Americans and Latinos.

93 isk for Caucasians and attenuated risk among African Americans and people with type II diabetes.

94 pulations analysed exhibit no such trend, in African Americans and Puerto Ricans, we find a significa

95 population sample of 1,327 participants (60% African Americans and women) who had a clinical evaluati

96 cipants were 113 lean, overweight, and obese African-American and Caucasian-American adults without d

97 FN3K and/or FN3KRP in Europeans, and G6PD in African-Americans and Hispanics) and we identified an Af

98 f a regulatory polymorphism from DNASE1L3 in African-Americans and Latinos.

99 41.2 +/- 13.1 years, 59.5% were women, 25.5% African American, and 64.0% Hispanic.

100 1 years, 83% women, 57% Hispanic/Latino, 31% African American, and a baseline FBS of 9.3 +/- 2.4 poin

101 PRS were calculated from European, African American, and Ashkenazi Jewish (AJ) reference ca

102 tigated individual behaviors taken by white, African American, and Latino United States (US) househol

103 itions were more likely to be younger, to be African American, and to have hypertension, valvular hea

104 ncer patients, patients who are older, male, African American, and unmarried are at a greatest risk o

105 om 1,693 non-Hispanic white individuals, 385 African Americans, and 90 Hispanics with >=20 pack-years

106 us never in European Americans, one locus in African Americans, and one in Hispanic Americans.

107 her expression of ACE2 and TMPRSS2 in males, African Americans, and patients with diabetes mellitus p

108 uated from college, 55% were white, 35% were African-American, and 97% had insurance.

109 laims on government resources of immigrants, African-Americans, and Latinos.

110 African Americans are at greater risk for developing Alz

111 African Americans are at increased risk of cancer and as

112 African Americans are consistently found to have a lower

113 Black/African Americans are contracting and dying from COVID-1

114 A common belief is that African Americans are hyposensitive to pain compared to

115 ith SUD, especially individuals with OUD and African Americans, as having increased risk for COVID-19

116 ation groups based on race, including White, African American, Asian, Hispanic, Native American, Bi-

117 lished between April 2006 and May 2019 in 20 African, American, Asian, and Middle Eastern countries w

118 e to discern racial subgroup category (black/African American [AUC, 0.84], and white, non-Hispanic [A

119 ass was inversely associated with SIClamp in African Americans (beta = -0.05, SE = 0.03, P = 0.04) bu

120 eg fat) was associated with lower SIClamp in African Americans (beta = -0.45, SE = 0.11, P < 0.001) b

121 AAT) was associated with a higher SIClamp in African Americans (beta = 0.11, SE = 0.05, P = 0.02) but

122 impact on the progression of COVID-19 in the African American (black) community, and suggest a multif

123 are living with HIV-nearly one-half of Black/African American (Black) transgender women are living wi

124 African American/Black and Hispanic populations experien

125 African American/Black and Hispanic populations experien

126 et as: American Indian/Alaska Native, Asian, African American/Black, Hispanic/Latino, and Native Hawa

127 of vitamin D on breast cancer subtypes among African-American/black women, who tend to develop more a

128 en 6 and 11 years old in four ethnic groups (African American, Burmese, Caucasian, and Hispanic) from

129 correlated with increased CSF IL-9 levels in African Americans but not Caucasians.

130 Multi-Ethnic Study of Atherosclerosis (MESA) African Americans, but it did not replicate in African A

131 ncer (CRC) screening before age 50 years for African Americans, but there are few data on screening u

132 modest overlap across European-Americans and African-Americans, but the genetic liability for CD conv

133 Overall, only <= 9.5% of African American cases and controls from the SCCS drank

134 In a whole-genome scan in 899 African-American cases and 1155 African-American control

135 via utilization of a sustainable, low-cost, African American-centric organ donation educational vide

136 e samples from 148 predominantly low-income, African American children (aged 5-17 years) with establi

137 Clearance is also lower in African American children 7-13 years of age.

138 irty-three nonsevere and 22 severe asthmatic African American children were included in an epigenome-

139 ositive) Th cells from 59 obese Hispanic and African American children with asthma and 61 normal-weig

140 ith asthma and 61 normal-weight Hispanic and African American children with asthma underwent quantifi

141 erved between nonsevere and severe asthma in African American children, a subset of which may be usef

142 ion findings in a cohort of 72 predominantly African American children, and in 432 children from a Eu

143 Atopic dermatitis (AD) is more common among African American children.

144 ng study in partnership with a predominantly African American church in Durham, North Carolina.

145 exhibit a significant association within the African American cohort.

146 ic data in the Jackson Heart Study (JHS), an African-American cohort (n = 1,928), with replication in

147 ed IBD status in European, AJ, Hispanic, and African American cohorts in BioMe.

148 rs76723693 (G6PD) in the two largest TOPMed African American cohorts, and we replicated the rs767236

149 or even healthy ANA- counterparts, or among African American cohorts.

150 95% CI 1.55-1.98; p < 0.001), being black or African American compared to white (OR 1.50; 95% CI 1.31

151 theta 2 (GSTT2) mRNA in squamous mucosa from African American compared with European American individ

152 t in the highest quartile was more likely in African Americans compared to whites (adjusted odds rati

153 ore, disease transition is higher among ANA+ African Americans compared with ANA+ European Americans.

154 likelihood of having an approved donor among African Americans compared with Caucasians.

155 JAK2 mutations in lung adenocarcinomas among African Americans compared with European Americans.

156 heat and emergency hospital admissions among African Americans compared with Whites.

157 Older age, male sex, and being black or African American (compared to being white) remained sign

158 In obese African Americans, compared to obese European Americans,

159 The 4323 included patients (29% women, 60% African American) contributed 30 007 person-years.

160 4323 patients (29% women, 60% African-American) contributed 30 007 person-years.

161 scan in 899 African-American cases and 1155 African-American controls, we confirm that African-Ameri

162 tcomes, potentially increasing the number of African American donors.

163 Hispanics/Latinos, isolation-by-distance in African Americans, elevated levels of relatedness and ho

164 lysis identified recipient age, male gender, African American ethnicity, donor age, and cold ischemia

165 Prevalence of African American ethnicity, end-stage renal disease, dia

166 Young age and African-American ethnicity increased false negative rate

167 In contrast, ANA+ healthy African Americans exhibited elevated expression of T-cel

168 A 14-year-old African American female presented with fatigue, easy bru

169 ibrate interaction on MACE was replicated in African Americans from ACCORD (N = 585, P = 0.02) and in

170 rican Americans, but it did not replicate in African Americans from the Cardiovascular Health Study (

171 ng 1801 cancer cases and 3337 controls among African Americans from the Southern Community Cohort Stu

172 bination maps for European Americans and for African Americans from TOPMed sequence data from the Fra

173 otype, and insulin sensitivity data from the African American Genetics of Metabolism and Expression (

174 hort of 230 African Americans (AAs) from the African American Genetics of Metabolism and Expression c

175 stry was associated with outcomes within the African American group.

176 Compared with Caucasians, African Americans had lower odds of sarcopenia and low S

177 African Americans had significantly higher prevalence an

178 Among patients with recent diagnosis of SUD, African Americans had significantly higher risk of COVID

179 Compared to older Caucasians, older African Americans have higher risks of developing Alzhei

180 o analysis at the organ-level indicates that African-Americans have a stronger multimorbidity network

181 ng 2385 participants (65% PWH, 95% male, 68% African American), higher CD45RO+ memory CD4+ T cells an

182 t difference in differences analysis between African American, Hispanic, and Asian patients receiving

183 errepresented groups (URGs), including Black/African Americans, Hispanic/Latinx, Pacific Islanders, a

184 an ethnicity- and gender-balanced sample of African Americans, Hispanics and non-Hispanic Whites usi

185 < 0.001) as compared to non-ACOs for whites, African Americans, Hispanics, and Asians in both the pre

186 reported in 7 studies, including Caucasians, African Americans, Hispanics, Korean Americans, Australi

187 associated with HbA1c (GCK in Europeans and African-Americans, HK1 in Europeans and Hispanics, FN3K

188 6; 95% confidence interval [CI], 1.16-1.37), African American (HR 1.26; 95% CI, 1.15-1.39), and other

189 Increasing African American IBD case-collections should be prioriti

190 not associated with the risk of cancer among African Americans in our study.

191 African Americans in the early screening group were mode

192 Among 10,232 African Americans in the early screening group who were

193 erving hospitals.Conclusions: Critically ill African American individuals are disproportionately care

194 ed whether the esophageal squamous mucosa of African American individuals has features that protect a

195 pitals, there was little temporal change for African American individuals in minority-serving hospita

196 sed levels of GSTT2 in esophageal tissues of African American individuals might protect them from GER

197 ral trends was particularly noticeable among African American individuals, where each additional cale

198 hese with variants within the GSTT2 locus in African American individuals.

199 xplain the higher cardiometabolic risk among African Americans is unknown.

200 prevalence, compared with white persons, for African Americans, Japanese Americans, and Native Hawaii

201 dietary factors in relation to NAFLD risk in African Americans, Japanese Americans, Latinos, native H

202 Because most African American kidney donor candidates lacking hyperte

203 The exclusion of Blacks/African-Americans, Latinx/Hispanics, and Indigenous peop

204 f 109 participants, 87% were male, 32% black/African American, median (range) age was 28 (range, 19-6

205 al immunochemical test (FIT) screening among African American members of the Kaiser Permanente Northe

206 We compared data from African American members screened when they were 45-50 y

207 The cohort included 8726 men, including 2280 African American men (26.1%) (median age, 63.2 years) an

208 Among African American men and non-Hispanic White men, respect

209 e most commonly diagnosed cancer in men with African American men disproportionally suffering from th

210 African American men possess short polyQ tracts signific

211 There is concern that African American men with low-risk prostate cancer may h

212 CA1, XPC, JAG1, RPA1, POLE, ATM, and LIG1 in African American men, and POLQ, NEIL3, POLB, BRCA2, EXO1

213 ancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White m

214 her active surveillance is a safe option for African American men.

215 nal connectivity (rs-fc) were collected from African American (n = 131) and white (n = 685) cognitive

216 C], 0.931), Asian (n=557; AUC, 0.961), black/African American (n=651; AUC, 0.937), Hispanic/Latino (n

217 Africans (n = 4126) and African Americans (n = 5007) were genotyped on high-dens

218 asthma exacerbations in 3 additional groups: African Americans (n = 803 and n = 563) and Latinos (n =

219 ll allotypes that are common in European and African Americans (n = 97), which revealed a broad conti

220 ut microbiome, proteome and metabolome in 88 African-American newborns using faecal samples collected

221 t signals for European Americans and one for African Americans on GAD-2 score.

222 minority-serving hospitals as those with an African American or Hispanic ICU census more than twice

223 SD, 14.4), 25.9% were female, and 75.4% were African-American or Hispanic.

224 a cited for this article varied from blacks, African Americans, or both; for consistency, we use Afri

225 t in BVA was significantly faster in men and African Americans (P < .05).

226 all cohort (P = .008) and specifically among African Americans (P = .007).

227 ffect on registration between Caucasians and African Americans (P = 0.62).

228 Compared to white participants, African American participants had greater neurodegenerat

229 The African American patient group showed increases in extra

230 ential indications for genetic testing in an African American patient with chronic kidney disease who

231 up-regulated in primary prostate tumors from African American patients, who are at an increased risk

232 ta-Catenin pathway seem to be independent in African American patients.

233 pment, which has been frequently observed in African American patients.

234 nt signaling activation has been observed in African American patients.

235 Applied on African-American pedigrees from the Cleveland Family Stu

236 ica has become more diverse in recent years, African American physicians remain largely underrepresen

237 severe in this group, and the second from an African American population in the United States.

238 ence of colorectal polyps in a predominantly African American population with inflammatory bowel dise

239 allergens (OR, 2.44; 95% CI, 1.49-4.05), and African American race (OR, 2.04; 95% CI, 1.19-3.47).

240 e interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), As

241 tration; while compared with Caucasian race, African American race was not (OR, 0.22; 95% CI, 0.22-0.

242 Among patients with asthma, male sex, African American race, and history of diabetes mellitus

243 We examined whether self-identified African American race/ethnicity was predictive of these

244 for adverse outcomes due to hyperfiltration: African American recipients (aHR 1.10, 95% CI 0.70-1.73,

245 gs identify a brain basis for higher pain in African Americans related to interpersonal context and e

246 European American and African American samples were then meta-analyzed; the as

247 are ALCAM, PF-4, properdin, and VCAM-1 among African-Americans, sE-selectin, VCAM-1, BFL-1 and Hemope

248 yposensitive to pain compared to Whites, but African Americans show increased pain sensitivity in cli

249 African Americans showed markedly lower expression of th

250 on were associated with negative emotion for African American students, but only interpersonal discri

251 ey disease progression in human cohorts: the African American Study of Kidney Disease and Hypertensio

252 Mean central corneal thickness for African American subjects (555.7 +/- 40.0 mum; n = 318)

253 African American subjects differed from European America

254 African American subjects have thinner corneas than whit

255 ith AD risk or control among self-identified African American subjects in either cohort, nor did an A

256 AD was more common among self-identified African American subjects than non-Hispanic white subjec

257 D prevalence or poorer disease control among African American subjects.

258 cestry is predictive of these outcomes among African American subjects.

259 Black/African American surgeons were 56% less likely [odds rat

260 erapy-related cardiomyopathy specifically in African-American survivors.See related commentary by Bro

261 cally detected AF was substantially lower in African American than in white participants, without or

262 tate cancer, such as the higher mortality in African Americans than Caucasians.

263 Hepatic insulin clearance is 67% lower in African Americans than European Americans.

264 ension was approximately a decade earlier in African Americans than in European Americans or Mexican

265 droxyvitamin D [25(OH)D] tend to be lower in African Americans than in non-Hispanic whites, but wheth

266 9% in Chinese and was significantly lower in African Americans than in whites, in both unadjusted and

267 tourinary system disorders is stronger among African Americans than others.

268 nd mortality, is significantly greater among African Americans than whites in the United States.

269 ulin sensitivity may have a genetic basis in African Americans that is reflected in the pattern of bo

270 Alternatively, among African Americans the 24% in haplogroup L2 experienced l

271 Among HT African-Americans, three of the 12 single nucleotide pol

272 Americans, or both; for consistency, we use African Americans throughout.).

273 associated with increased susceptibility of African Americans to SARS-CoV-2.

274 more diverse training datasets that include African American Vernacular English-to reduce these perf

275 For LDKT, non-Hispanic African American Veterans were less likely to receive an

276 nd histologic consequences of aging in black African-American volunteers.

277 g free of hypertension at 85 years of age in African Americans was less than half that in European Am

278 Higher pain report in African Americans was mediated by discrimination and inc

279 African Americans were more likely than whites to develo

280 mean +/- SD age: 54 +/- 6 y, 57% women, 27% African American) were followed for incident CAD through

281 nucleotide excision repair pathway genes in African Americans, whereas >40% of tumors had mutations

282 in 2018 with data from previously unscreened African American, white, Hispanic, and Asian/Pacific Isl

283 mpleted screening than previously unscreened African Americans, whites, and Hispanics 51-56 years old

284 comparable to those of previously unscreened African Americans, whites, Hispanics, and Asian/Pacific

285 Proportions of African Americans who participated in early (aged 45-50

286 5 African-American controls, we confirm that African-Americans who inherit segments of the genome of

287 ts (death: 6.6%, hospitalization: 30.1%) and African Americans with COVID-19 and SUD had worse outcom

288 African Americans with elevated saturated transferrin an

289 ginal increase in mutation rate in tumors in African Americans with increasing age.

290 Compared to Caucasians with NC, African Americans with NC had lower CSF tau, p-Tau(181)

291 ot have worse VA than those without PAU, and African Americans with PAU did not have worse VA or IOP

292 We included 95 patients (76% women, 86% African American) with SAPH.

293 ations were more likely to be younger, male, African American, with a higher American Society of Anes

294 Lupus is more prevalent in African American women and women in other ethnic minorit

295 African American women are more likely to die of breast

296 s currently 0.053-4%, with a predominance in African-American women and has been linked to low socioe

297 Incidence is higher in African-American women and in women with older maternal

298 festyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23-35 years of age.

299 Study 1 involved 90 rural African American young adults, 25 years of age (52% fema

300 (52% female), and study 2 involved 82 urban African American youths, 13 to 14 years of age (66% fema